Pioneering ‘In Utero’ Treatment For Fatal Enzyme Deficiency Proves Successful In Saving Baby’s Life

Deposit Photos

In a groundbreaking medical achievement, an unborn baby has become the first in history to be treated for Pompe disease, a rare genetic condition that had previously claimed the lives of her two older siblings.

This pioneering procedure, involving treatment through the umbilical cord, not only prevented the infant’s death but also signifies a potential life-saving standard of care that is both safe and effective for both mother and baby.

The parents of 16-month-old Ayla, residing in Canada, experienced immense relief when their daughter was born without any signs of Pompe disease. This inherited condition, stemming from a defective gene copy, affects fewer than 1 in 100,000 infants and is notorious for its often fatal consequences.

Pompe disease, categorized as a “lysosomal storage disorder,” leads to the accumulation of toxins in tissues, posing a severe threat to affected individuals.

Conventionally, treatment for Pompe disease initiates after birth and involves a method known as enzyme replacement therapy (ERT). This therapy entails injecting an enzyme, GAA, critical for health heart function. Since fetuses and infants like Ayla are unable to produce this enzyme, toxic buildups of glycogen, the storage form of sugars such as glucose, can occur, resulting in damage to the heart and the onset of myocarditis.

The consequences of this condition are dire, making it challenging for small hearts to effectively pump blood, leading to muscle weakness. Typically, death occurs within two years for those afflicted with Pompe disease. However, the remarkable turn of events in Ayla’s case offers newfound hope for affected families.

In March of 2021, Ayla’s mother embarked on an unprecedented journey at an Ottawa maternal hospital. Over the ensuing weeks, she received six injections of an infant-Pompe drug known as alglucosidase alfa directly into the umbilical vein. This delivery method, already established for treating fatal anemia, represented a novel approach for addressing Pompe disease in utero.

Ayla was born as schedule, exhibiting no signs of the disease that had plagued her family. Remarkably, she has met all normal developmental milestones and shows no loss of motor function. While continuing to receive regular enzyme replacement therapy, Ayla’s story stands as a testament to the success of this groundbreaking intervention.

The significant results of Ayla’s treatment have been documented and published in the prestigious New England Journal of Medicine, marking a pivotal moment in medical history.

“Our results are consistent with in utero ERT attenuating or even halting the disease process in the fetal period,” the doctors wrote in their case report.

“Furthermore, although it is accepted that starting treatment as early as possible improves outcomes in patients with lysosomal storage diseases … our results suggest that moving the window for therapeutic intervention into the prenatal period may further improve postnatal outcomes.”

This pioneering procedure not only saved Ayla’s life but also opens doors to a new era of possibilities for treating Pompe disease and potentially other genetic conditions in utero, providing renewed hope for families facing similar challenges.